Product
NI-1801
1 clinical trial
3 indications
Indication
Ovarian CancerIndication
Triple-Negative Breast CancerIndication
Non-squamous non-small cell lung cancerClinical trial
A Phase 1, Open-label, Dose Finding Study of NI-1801, a Bispecific Mesothelin x CD47 Engaging Antibody, in Patients With Mesothelin Expressing Solid CancersStatus: Recruiting, Estimated PCD: 2025-06-30